During a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated for sepsis in a 24-bed medical-surgical intensive care unit. Drotrecogin alfa, activated was administered 46 times to 44 patients (3% of all intensive care unit admissions). Eighty-six percent of patients were on vasopressors; 95% were mechanically ventilated. Mean Acute Physiology and Chronic Health Evaluation II score was 22.0 at admission and 21.9 during the 24 hours before drug administration. The 28-day all-cause mortality was 36.4% and hospital mortality was 43.2%, trending higher (P= .10) than in the PROWESS study, which can be attributed to clinical use in patients who would not have met PROWESS study inclusion criteria. Failure to complete a 96-hour infusion of drotrecogin alfa, activated and transfer from another hospital or nursing home before treatment were associated with poor outcome. Total cost of hospital care, including mean drotrecogin alfa, activated drug cost of $7312, exceeded reimbursement by a mean of $18 227.
Martin GS, Mannino DM, Eaton S, Moss M.The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-1554.
2.
Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001:9 (suppl7):S109-S116.
3.
Bernard GR, Vincent JL, Laterre PF, et al.Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis. N Engl J Med. 2001;344:699-709.
4.
Wood KA, Huang D, Angus DC. Improving clinical trial design in acute lung injury. Crit Care Med. 2003;31(suppl4): S305-S311.
5.
Project Impact Information. Available at: http://www.projectimpacticu.cc/. Accessed December 16, 2003.
6.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-826.
7.
LeGall JR, Lemeshow S, Saulnier F.A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-2963.
8.
ACCP/SCCM consensus conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
9.
Schmidt G, Bates B, McCollam JS, Steingrub J.Clinical use of drotrecogin alfa (activated): patients treated in MERCURY differ from those in PROWESS. Crit Care Med. 2003;13(suppl):A116.
10.
Quap CW, Tran JI, Ham CW, Gupta V.The use of recombinant human activated protein C, drotrecogin alfa (activated) in the management of patients with sepsis in the community hospital setting. Crit Care Med. 2003;13(suppl): A103.
11.
Riker RR, Fraser GL, Schlicting DE, Wilkins SL. Cutting edge science from the clinical trial to the bedside: first 8 months use of drotrecogin alpha activated (APC) for severe sepsis. Crit Care Med. 2003;13(suppl):A103.
12.
Swerlein A, Conty W, McClusky C, Gerlach A, Shirk MB. Initial experience with drotrecogin alfa activated in two large tertiary care facilities. Crit Care Med. 2003;13(suppl): A104.
13.
Wittbrodt E, Rose C, Birnbaum P, Verceles A, Patrick H.Experience with Drotrecogin alfa activated (DAA) in a tertiary care hospital. Crit Care Med. 2003;13(suppl):A104.
14.
Macias W, Helterbrand JD, Derchak PA. Influence of patient heterogeneity on treatment effect of drotrecogin alfa (activated) in PROWESS. Crit Care Med. 2003;13(suppl):A105.
15.
Wheeler A, Steingrub J, Linde-Zwirble W, McCollam JS, Zeckel M.Prompt Administration of drotrecogin alfa (activated) is associated with improved survival. Crit Care Med. 2003;13(suppl):A120.
16.
Vincent JL, Levy MM, Macias WL, Trzaskoma BL. Early intervention with drotrecogin alfa (activated) improves survival benefit. Crit Care Med. 2003;13(suppl):A123.
17.
McGee WT, Higgins T, Askew E.Quality of outcome in patients admitted to the ICU from long-term facilities. Crit Care Med. 2003;(suppl 2):A141.
18.
Xigris [package insert]; Indianapolis, Ind: Eli Lilly and Company, 2003.
19.
Higgins TL. Severity of illness indices and outcome prediction: development and evaluation. In: Grenvik A, Ayres SM, Holbrook PR, Shoemaker WC, eds. Textbook of Critical Care, 4th ed.Philadelphia, Pa: W. B. Saunders Company; 2000:2069-2083.
20.
Dragsted L, Jorgensen J, Jensen NH, et al.Interhospital comparisons of patient outcome from intensive care: importance of lead-time bias. Crit Care Med. 1989;17:418-422.
21.
Escarce JJ, Kelley MA. Admission source to the medical intensive care unit predicts hospital death independent of APACHE II Score. JAMA. 1990;264:2389-2394.
22.
Barie PS, Hydo LJ, Fischer E.Development of multiple organ dysfunction syndrome in critically ill patients with perforated viscus: predictive value of APACHE severity scoring. Arch Surg. 1996;131:37-43.
23.
Rutledge R, Fakhry SM, Rutherford EJ, et al.Acute Physiology and Chronic Health Evaluation (APACHE II) score and outcome in the surgical intensive care unit: an analysis of multiple intervention and outcome variables in 1238 patients. Crit Care Med. 1991;19:1048-1053.
24.
Wagner DP, Knaus WA, Harrell FE, Zimmerman JE, Watts C.Daily prognostic estimates for critically ill patients in intensive care units: results from a prospective, multicenter, inception cohort analysis. Crit Care Med. 1994;22:1359-1372.
25.
Murphy-Filkins RL, Teres D, Lemeshow S, Hosmer DW. Effect of changing patient mix on the performance of an intensive care unit severity-of-illness model: how to distinguish a general from a specialty intensive care unit. Crit Care Med. 1996;24:1968-1973.
26.
Knaus WA, Harrell FE, LaBrecque JF, et al.Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. Crit Care Med. 1996;24:46-56.
